In such cases, the reduction of tumor mass via RT either directly, via apoptotic/necrotic death of tumor cells, or indirectly, via RT-induced antitumor cytotoxic CD8+ T cells, could further improve the clinical efficacy of anti-PD-1/PD-L1 treatment. Here, CD8A is linked to neoplasm.